Sensorial Neurodegeneration

Group leader: Javier Ruiz Ederra, Ph.D.

Biodonostia HRI javier.ruizederra@osakidetza.eus

Aims and lines of research

Vision is one of the human being’s main sensory skills. The Research Group is focusing its study on diseases that affect our sense of sight, with Retinitis Pigmentosa as its main line of research.

Retinitis Pigmentosa is the most common inherited retinal degenerative disorder, with a worldwide prevalence of approximately 1 in every 4000 individuals. It is characterised by progressive dysfunction associated with the loss of rods and/or cones leading to atrophy of the retina and loss of vision. There is wide genetic heterogeneity within Retinitis Pigmentosa with over 80 genes identified to date. Most cases are monogenic and the genetic causes of approximately 35% of Retinitis Pigmentosa cases are currently unknown. Their molecular characterisation represents a real challenge. From a therapy point of view, there is no standardised, effective treatment for this eye disease right now but the discovery of molecular causes has allowed different trials to be designed on animal models and more recently on humans, with promising results.

Another area of study focuses on cataracts that represent the main cause of loss of vision in people over 55 years old worldwide. This is a multi-factor process where modifications to the structural crystalline proteins bring about aggregation, fragmentation and precipitation processes leading to the cataract forming. Right now, the only effective treatment is surgery. This is one of the most frequent outpatient surgeries carried out in industrialised countries and the most common outpatient procedure in Spain where over 260,000 cataract operations are performed each year, costing over 260 million Euros/year.

Furthermore, working with pharmacometric and software companies, the Research Group is developing computer simulated predictors of ocular pharmacodynamics in order to predict how drugs will behave in the eye as an alternative to experimenting on animals.

Main lines of research

  • Molecular diagnosis of patients with Retinitis Pigmentosa using high-throughput screening techniques (HRM and DNA arrays) and Next Generation Sequencing (targeted sequencing using panels of Retinitis Pigmentosa genes and/or Whole Exome Sequencing, WES).
  • Studies on Retinitis Pigmentosa mouse models.
    • Elements regulating the gene expression (microRNAs; (microRNAs, lncRNAs etc.).
    • In vitro and in vivo gene transfer assays.
  • Molecular study of molecular pathways involved in cataract development factors.
    • Implication of aquaporins 1 and 5 in cataract development.
    • Study of risk factors for posterior capsular opacification after cataract surgery (secondary cataract).
  • Development of computer simulated predictors for ocular pharmacodynamics.

Team Members

Name Surname Center E-mail
Txomin Alberdi Ibarloza Donostialdea IHO txomin.alberdiibarloza@osakidetza.eus
Lucía Bascarán Oteiza Donostialdea IHO lucia.bascaranoteiza@osakidetza.eus
Leire Escudero Arraras Biodonostia HRI leire.escudero@biodonostia.org
Maitane Ezquerra Inchausti Biodonostia HRI maitane.ezquerra@biodonostia.org
Cristina Irigoyen Laborra Donostialdea IHO cristina.irigoyenlaborra@osakidetza.eus
Leire Juaristi Eizmendi Donostialdea IHO leire.juaristieizmendi@osakidetza.eus
Itziar Martínez Soroa Donostialdea IHO itziar.martinezsoroa@osakidetza.eus
Javier Mendicute del Barrio Donostialdea IHO javier.mendicutedelbarrio@osakidetza.eus
Iñaki Rodríguez Aguirreche Donostialdea IHO ignacio.rodriguezaguirreche@osakidetza.eus
Miguel Ruiz Miguel Donostialdea IHO miguel.ruizmiguel@osakidetza.eus

 

Scientific Output

Originals

Published: 10 / 15

The PLGA implant as an antimitotic delivery system after experimental trabeculectomy.

Rodríguez-Agirretxe I, Vega SC, Rezola R, Vecino E, Mendicute J, Suarez-Cortes T, Acera A.

Invest Ophthalmol Vis Sci. 2013; 54: 5227-5235. FI: 3.661 (Q1).

Genetic High Throughput Screening in Retinitis Pigmentosa based on High Resolution Melting (HRM) Analysis.

Anasagasti A, Barandika O, Irigoyen C, Benitez BA, Cooper B, Cruchaga C, López de Munain A, Ruiz-Ederra J.

Exp Eye Res. 2013; 116: 386-394. FI: 3.017 (Q1).

Rotational stability and visual quality in eyes with Rayner toric intraocular lens implantation.

Alberdi T, Macías-Murelaga B, Bascarán L, Goñi N, de Arregui SS, Mendicute J.

J Refract Surg. 2012; 28 (10): 696-701. FI: 2.781 (Q1).

Efficacy and stability of AT TORBI 709 M toric IOL.

Bascaran L, Mendicute J, Macias-Murelaga B, Arbelaitz N, Martinez-Soroa I.

J Refract Surg. 2013; 29 (3): 194-199. FI: 2.781 (Q1).

Vector analysis of astigmatism correction after tonic intraocular lens implantation.

Krall EM, Arlt EM, Hohensinn M, Moussa S, Jell G, Alio JL, Plaza-Puche AB, Bascaran L, Mendicute J, Grabner G, Dexl AK.

J. Cataract. Refract. Surg. 2015; 41: 790-799. FI: 2.722 (Q1).

Objective Optical Quality Analysis Using Double-Pass Technique in Pterygium Surgery.

Goni N, Bidaguren A, Macias-Murelaga B, Alberdi T, Martinez-Soroa I, Mendicute J.

Cornea. 2015; 34: 60-64. FI: 2.042 (Q2).

3p14 De Novo Interstitial Microdeletion in a Patient with Intellectual Disability and Autistic Features with Language Impairment: A Comparison with Similar Cases.

de la Hoz AB, Maortua H, García-Rives A, Martínez-González MJ, Ezquerra M, Tejada MI.

Case Rep Genet. 2015; 2015: 876348-0. FI: 0.000 (Q0).

Determination of phosphate concentration in glaucoma eye drops commercially available in Spain.

Martínez-Soroa I, de Frutos-Lezaun M, Ostra Beldarrain M, Egía Zurutuza A, Irastorza Larburu MB, Bachiller Cacho MP.

Archivos De La Sociedad Española De Oftalmología. 2016; 91: 363-371.

Determination of phosphate concentration and pH in artificial tear drops.

de Frutos-Lezaun M, Martínez-Soroa I, Ostra Beldarrain M, Egia Zurutuza A, Irastorza Larburu MB, Fernandez Iriarte A, Bachiller Cacho MP.

Archivos De La Sociedad Española De Oftalmología. 2016; 91: 372-378.

Increased aquaporin 1 and 5 membrane expression in the lens epithelium of cataract patients.

Barandika O, Ezquerra-Inchausti M, Anasagasti A, Vallejo-Illarramendi A, Llarena I, Bascaran L, Alberdi T, De Benedetti G, Mendicute J, Ruiz-Ederra J.

Biochimica Et Biophysica Acta-Reviews On Cancer. 2016; 1862: 2015-2021. FI: 9,452 (Q1).

Reviews

Published: 1 / 1

Current mutation discovery approaches in Retinitis Pigmentosa.

Anasagasti A, Irigoyen C, Barandika O, López de Munain A, Ruiz-Ederra J.

Vision Res. 2012; 75: 117-29. FI: 2.381 (Q2).

Editorials

Published: 0 / 0

Letters

Published: 0 / 0

Others

Published: 0 / 0

Projects

Projects 2 / 2

Caracterización genético-molecular de la Retinosis Pigmentaria en Gipuzkoa.

Investigador Principal: Javier Ruiz-Ederra. Entidad Financiadora: Asociación de Afectados por Retinosis Pigmentaria de Gipuzkoa (BEGISARE). Año inicio: 2011. Año final: 2015.

Estudio de los microRNAs en pacientes y en modelos murinos de retinosis pigmentaria: nuevas dianas terapéuticas.

Investigador Principal: Javier Ruiz Ederra. Entidad Financiadora: ISCIII Instituto de Salud Carlos III. Año inicio: 2014. Año final: 2016.